China’s National Medical Products Administration has granted marketing authorization for olaparib as a first-line maintenance treatment for adult patients with newly diagnosed advanced germline or somatic BRCA-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to frontline platinum-based chemotherapy.
The UK’s National Institute for Health and Care Excellence has approved olaparib for the maintenance treatment of adult patients with relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease responded to platinum-based chemotherapy and harbor BRCA1/2 mutations.
Sarah Crafton, MD, discusses the role of secondary surgical cytoreduction in recurrent ovarian cancer.
John Hays, MD, PhD, discusses ongoing research with immunotherapy in ovarian cancer, challenges with determining predictive biomarkers of response, and promising emerging modalities.
Larry J. Copeland, MD, discusses how therapy for patients with ovarian cancer has evolved in recent years.
Ritu Salani, MD, discusses the evolution of up-front chemotherapy, as well as the roles of primary debulking surgery and neoadjuvant chemotherapy in ovarian cancer.
David O’Malley, MD, discusses clinical trials in ovarian cancer and others under investigation.
Leigha Senter, MS, LGC, discusses the current state of genetic testing for patients with ovarian cancer.
Secondary cytoreduction followed by chemotherapy was not found to improve overall survival compared with chemotherapy alone in patients with platinum-sensitive recurrent ovarian cancer.
As PARP inhibitors have now moved into the frontline maintenance setting in ovarian cancer, researchers are now seeking to even further capitalize on use of these agents, including indications in treatment-naïve patients.